Pancreatic Cancer Research

ResearcherTottori UniversityActive in the last 2 years

Masaki Morimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5937-4056; OpenAlex author ID A5101457576. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 4 papers

Papers 14

  1. The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic canc… Co-author DOI 10.1186/s12957-026-04370-y↗
  2. Impact of CD73+CD39+ B Cells on Immune Evasion in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18437↗
  3. The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer. Co-author DOI 10.21873/cdp.10573↗
  4. Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer. Co-author DOI 10.21873/invivo.14436↗
  5. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101608↗
  6. Modified geriatric nutritional risk index in patients with pancreatic cancer: a propensity score-matched analysis. Co-author DOI 10.1186/s12885-022-10071-y↗
  7. Geriatric nutritional risk index as a prognostic factor in patients with recurrent pancreatic cancer. Co-author DOI 10.1371/journal.pone.0271073↗
  8. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Co-author DOI 10.1038/s41598-021-94711-6↗
  9. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1186/s12893-020-00976-5↗
  10. Evaluation of Blood Supply with Indocyanine Green Fluorescence in Resection for Concurrent Gastric and Pancreatic Cancer: A Case Report. Co-author DOI 10.33160/yam.2021.02.017↗
  11. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.11.028↗
  12. Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients. Co-author DOI 10.33160/yam.2020.02.011↗
  13. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13260↗
  14. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Can… Co-author DOI 10.21873/anticanres.12883↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teruhisa Sakamoto · 13 shared papers, 2018–2026 · strength 2.08
  2. Yoshiyuki Fujiwara · 10 shared papers, 2018–2023 · strength 1.21
  3. Mikiya Kishino · 4 shared papers, 2026 · strength 1.03
  4. Takehiko Hanaki · 7 shared papers, 2020–2023 · strength 0.88
  5. Takuki Yagyu · 5 shared papers, 2019–2026 · strength 0.66
  6. Yoshiyuki Fujiwara · 2 shared papers, 2026 · strength 0.53
  7. Teppei Sunaguchi · 3 shared papers, 2022–2023 · strength 0.44
  8. Ei Uchinaka · 4 shared papers, 2018–2021 · strength 0.39
  9. Yuki Murakami · 3 shared papers, 2021–2022 · strength 0.39
  10. Yoshihisa Umekita · 2 shared papers, 2020–2026 · strength 0.34
  11. Joji Watanabe · 3 shared papers, 2019–2021 · strength 0.31
  12. Tatsuya Matsura · 2 shared papers, 2020–2023 · strength 0.27
  13. Yoshiyuki Fujiwara · 1 shared paper, 2026 · strength 0.26
  14. Yoshiyuki Fujiwara · 1 shared paper, 2026 · strength 0.23
  15. Masataka Amisaki · 2 shared papers, 2018–2019 · strength 0.17
  16. Kazushi Hara · 1 shared paper, 2023 · strength 0.17
  17. Hiroyuki Kugoh · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.